Genmab — Marts 2020
-
Sylke Maas (BioNTech):
That is the DuoBody, we are - you refer to PD-L1 4-1BB DuoBody which we are developing in cooperation with our partner Genmab. We are pretty advanced in our dose escalation. So have cleared a number of dose levels which were planned and the data disclosure presentation would definitely include data, referring to safety of different doses, probably also the Phase II dose.
-
don't think so, BioNTech SE (NASDAQ:BNTX) Q4 2019 Results Earnings Conference Call March 31, 2020 8:00 AM ET =14.00 here https://seekingalpha.com/article/4335275-biontech-ses-bntx-ceo-ugur-sahin-on-q4-2019-earnings-call-transcript?part=single
-
Det ender nærmest med en oms på 200% over normal. Så der er da godt gang i den....
-
-
Jan købte aktier
-
Ja dygtig gjort
-
@Pensionisten you know for many many years now that these warrants were issued, i don´t understand why you keep complaining about them each time some are exercised...
-
Agree E L
-
Jeg tror på en aftale
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind